ACQUISITIONS and MERGERS

In the past decade or so, the additive manufacturing industry has been characterized by an ever-increasing number of hardware players trying to capture their own share of the market. While there were signs of consolidation in the early 2010s, given major moves by industry leaders like Stratasys and 3D Systems, AM has instead seen a consistent stream of newcomers with their own innovative takes on AM, such that IDTechEx now segments their 3D printing hardware forecast by seventeen different categories to account for such diversity.

“The acquisition of Somryst aligns seamlessly with Nox’s mission of promoting science-based solutions that address chronic diseases through sleep care management. As an outcomes-driven company with ten years of real-world data, it was important for us to find a solution with equal depth in validation and outcomes data, thereby setting it apart from other CBT-I solutions,” said Sigurjon Kristjansson, CEO of Nox Health.

“We’re thrilled to accelerate our next phase of growth with a partner like Medtronic who shares our goal of simplifying diabetes management to make life easier for the customers we serve,” said Jesse J. Kim, CEO and founder of EOFlow. “Together, we’ll work to advance innovation in wearable insulin patch technology to expand our reach to more individuals around the world living with diabetes. With a global footprint in over 100 countries, ability to scale up manufacturing quickly, and advanced software and sensor capabilities, Medtronic is the ideal strategic partner for EOFlow.” 

“The acquisition of Somex Automation is a milestone for our company,” said Robbie Atkinson, CEO of Medical Manufacturing Technologies. “We are excited to bring a strong business with highly skilled employees into our family.”

“The acquisition reflects our investors’ commitment to the long-term growth and development of accūrō Solutions as the premiere service provider in the medical bill review industry,” said Chris Feeney, Executive Board Member of accūrō Solutions.

The transaction provides Abbott with a complementary solution for treating vascular disease. CSI’s leading atherectomy system prepares vessels for angioplasty or stenting to restore blood flow.